Inmagene Biopharmaceuticals, a China-based global clinical-stage biotechnology company, announced on Sunday that it has received approval from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor, to proceed to a Phase one clinical trial.
The company is producing the drug candidate to potentially treat immunological diseases.
The proposed Phase one study, a double-blind, randomised, placebo-controlled, single and multiple dose escalation study in healthy subjects, intends to explore the product's safety, tolerability, pharmacokinetics, and pharmacodynamics.
Sanofi's Nexviadyme gets EU approval in Pompe disease
Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval
Ipsen agrees to acquire Epizyme
ImmuPharma reports Avion seeking final FDA guidance ahead of Phase 3 trial of Lupuzor
Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial
Investigational Lenacapavir Receives Positive CHMP Opinion for People with Multi-Drug Resistant HIV